Infliximab
Brand: Remicade®, Inflectra®, Remsima®
NICE TA: 187
Indication: Crohn's disease, 1st line biologic (NICE TA187) and LMMG Recommendation
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Infliximab is recommended as a treatment option for adults with severe active Crohn’s disease whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease
Biosimilars of Infliximab (Version 1.1) (271.7 KiB)
Gastroenterology Biologics Pathway (Version 1.1) (355.6 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
